Transparency Market Research
Epilepsy Therapeutics Market Predicted to Reach USD 14.9 Bn by 2031 | Exclusive Report by Transparency Market Research
October 30, 2023 17:30 ET | Transparency Market Research
Wilmington, Delaware, United States, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global epilepsy therapeutics market is projected to surpass US$ 14.9 Bn by 2031,...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
October 30, 2023 08:03 ET | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
October 19, 2023 08:03 ET | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Completes Clinical Enrollment of First Cohort and Updates on Long-lasting Impact in First Patients Treated in Ongoing Phase I/II Trial of NRTX-1001 Cell Therapy for Drug-resistant Focal Epilepsy
October 19, 2023 08:00 ET | Neurona Therapeutics
First cohort treated in Ph I/II clinical trial of NRTX-1001 in adults with focal epilepsy, update on first patients'progress
Catalyst Pharmaceutical logo
Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida
October 16, 2023 08:03 ET | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that...
GMILogo_Vertical-Gradient.png
Brain Implants Market to hit USD 10 billion by 2032, says Global Market Insights Inc.
September 10, 2023 19:30 ET | Global Market Insights Inc.
Selbyville, Delaware, Sept. 10, 2023 (GLOBE NEWSWIRE) -- Brain Implants Market size is expected to be worth USD 10 billion by 2032. The growing burden of neurological disorders along with the...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
September 05, 2023 07:05 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Sept. 05, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress
August 31, 2023 08:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Research Nester Logo.jpg
Gabapentin Market revenue to reach USD 6 Billion by 2035, says Research Nester
August 29, 2023 06:00 ET | Research Nester
New York, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The gabapentin market size is poised to grow at a CAGR of over ~ 5 % from 2023 to 2035. The market is anticipated to garner a revenue of USD 6 billion by...
Transparency Market Research
Epilepsy Monitoring Devices Market to Exceed USD 737.0 Mn by 2031 to Grow at a CAGR of 4.6% Says, Transparency Market Research
August 17, 2023 06:04 ET | Transparency Market Research
Wilmington, Delaware, United States, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global epilepsy monitoring devices market is estimated to reach a value of US$ 737.0 Mn...